Abstract
Traditionally the brain has been viewed as being an immune-privileged organ. However, endogenous stimuli such as the presence of misfolded or aggregated proteins, as well as systemic inflammatory events may lead to the activation of microglial cells, the brain´s innate immune system, and, subsequently, to neuroinflammation. Alzheimer's disease, the leading cause of dementia, is characterized by amyloid beta deposition and tau hyperphosphorylation. Neuroinflammation in Alzheimer's disease has been identified as major contributor to disease pathogenesis. Once activated, microglia release several pro and anti-inflammatory mediators of which several affect the function and structure of the brain. Modulation of this microglial activation in Alzheimer's disease might open new therapeutic avenues.
Keywords: Alzheimer's, amyloid-β, cytokines, neuroinflammation, neurodegeneration, microglia.
Current Alzheimer Research
Title:Microglia in Alzheimer's Disease: The Good, the Bad and the Ugly
Volume: 13 Issue: 4
Author(s): Dario Tejera and Michael T. Heneka
Affiliation:
Keywords: Alzheimer's, amyloid-β, cytokines, neuroinflammation, neurodegeneration, microglia.
Abstract: Traditionally the brain has been viewed as being an immune-privileged organ. However, endogenous stimuli such as the presence of misfolded or aggregated proteins, as well as systemic inflammatory events may lead to the activation of microglial cells, the brain´s innate immune system, and, subsequently, to neuroinflammation. Alzheimer's disease, the leading cause of dementia, is characterized by amyloid beta deposition and tau hyperphosphorylation. Neuroinflammation in Alzheimer's disease has been identified as major contributor to disease pathogenesis. Once activated, microglia release several pro and anti-inflammatory mediators of which several affect the function and structure of the brain. Modulation of this microglial activation in Alzheimer's disease might open new therapeutic avenues.
Export Options
About this article
Cite this article as:
Tejera Dario and Heneka T. Michael, Microglia in Alzheimer's Disease: The Good, the Bad and the Ugly, Current Alzheimer Research 2016; 13 (4) . https://dx.doi.org/10.2174/1567205013666151116125012
DOI https://dx.doi.org/10.2174/1567205013666151116125012 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Research Progress on the Mechanisms of Combined Bevacizumab and Radiotherapy
Recent Patents on Anti-Cancer Drug Discovery Neuropeptide-Derived Antimicrobial Peptides from Invertebrates for Biomedical Applications
Current Medicinal Chemistry Development of Hedgehog Pathway Inhibitors (HPI) in Treatment of Cancer
Current Chemical Biology In Vivo Inhibition of the Estrogen Sulfatase Enzyme and Growth of DMBA-Induced Mammary Tumors by Melatonin
Current Cancer Drug Targets Urokinase-type Plasminogen Activator (uPA) and its Receptor (uPAR): Development of Antagonists of uPA / uPAR Interaction and their Effects In Vitro and In Vivo
Current Pharmaceutical Design Drug Tissue Distribution: Study Methods and Therapeutic Implications
Current Pharmaceutical Design Current Understanding of Epigenetics Driven Therapeutic Strategies in Colorectal Cancer Management
Endocrine, Metabolic & Immune Disorders - Drug Targets An Exposition of <sup>11</sup>C and <sup>18</sup>F Radiotracers Synthesis for PET Imaging
Current Radiopharmaceuticals Patent Annotations
Recent Patents on Anti-Cancer Drug Discovery Targeted Delivery of Tumor Suppressor microRNA-1 by Transferrin- Conjugated Lipopolyplex Nanoparticles to Patient-Derived Glioblastoma Stem Cells
Current Pharmaceutical Biotechnology Hypoxia in DU-145 Prostate Cancer Xenografts after Estramustine Phosphate and Radiotherapy
Current Radiopharmaceuticals Stem Cell-Like Brain Cancer Cells
Current Cancer Therapy Reviews Optical and Multimodal Peptide-Based Probes for In Vivo Molecular Imaging
Anti-Cancer Agents in Medicinal Chemistry Engineered Liposomes for Drug Delivery and Biomedical Imaging
Recent Patents on Nanomedicine AGE-RAGE System and Carcinogenesis
Current Pharmaceutical Design Natural Products Targeting EGFR Signaling Pathways as Potential Anticancer Drugs
Current Protein & Peptide Science Targeting the Phosphatidylinositol 3-Kinase/AKT Pathway for the Treatment of Multiple Myeloma
Current Medicinal Chemistry Measles Virus as An Oncolytic Vector Platform
Current Gene Therapy Design and Synthesis of Tetrahydroisoquinoline Derivatives as Anti-Angiogenesis and Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry L-Thyroxine Acts as a Hormone as well as a Prohormone at the Cell Membrane
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)